[THE INVESTOR]  Medytox  announced on Sept. 29 that its botulinum toxin and fillers have won approval for sales in four Central and South American countries this year.

The South Korean biopharma company’s botulinum toxin Medytoxin was granted permission in Chile and Mexico in July and August, respectively. The neurotoxin, commonly known as Botox, is injected mainly for cosmetic purposes such as reducing wrinkles.

Multiple types of its hyaluronic acid filler, mainly used to plump, soften and reduce creases and wrinkles, got the green light in Chile in March, Guatemala and Dominican Republic in June. 



Medytox entered the regional market in 2007.

By Hwang You-mee (glamazon@heraldcorp.com)